Evidence map›Paper›PMID 25479595›Full record

ArticleVirus research2015

MGMT enrichment and second gene co-expression in hematopoietic progenitor cells using separate or dual-gene lentiviral vectors.

Justin C Roth, Michael O Alberti, Mourad Ismail, Karen T Lingas, Jane S Reese, Stanton L Gerson

Open access · hybridAbstract read
In one paragraph

Article in Virus research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Justin C RothMolecular Virology Training Program, Case Western Reserve University, Cleveland, OH, USA; Division of Hematology and Oncology, Department of Medicine, Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH, USA; Division of Pediatric Infectious Diseases, Department of Pediatrics, University of Alabama at Birmingham, Birmingham, AL, USA. Electronic address: jroth@peds.uab.edu.
Michael O AlbertiDivision of Pediatric Infectious Diseases, Department of Pediatrics, University of Alabama at Birmingham, Birmingham, AL, USA. Electronic address: malberti@mednet.ucla.edu.
Mourad IsmailDivision of Hematology and Oncology, Department of Medicine, Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH, USA. Electronic address: mourad.ismail@gmail.com.
Karen T LingasDivision of Hematology and Oncology, Department of Medicine, Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH, USA. Electronic address: karen.lingas@case.edu.
Jane S ReeseDivision of Hematology and Oncology, Department of Medicine, Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH, USA; Seidman Cancer Center, University Hospitals Case Medical Center, Cleveland, OH, USA. Electronic address: jane.reese@case.edu.
Stanton L GersonDivision of Hematology and Oncology, Department of Medicine, Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH, USA; Seidman Cancer Center, University Hospitals Case Medical Center, Cleveland, OH, USA; National Center for Regenerative Medicine, Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH, USA; The Center for Stem Cell and Regenerative Medicine, Cleveland, OH, USA. Electronic address: stanton.gerson@case.edu.
Case Western Reserve University · USUniversity Hospitals Cleveland Medical Center · USUniversity of Alabama at Birmingham · US

Funding

TUMOR METABOLISM PROGRAMP30CA043703 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI MARK R CHANCE · 1987 to 2026
$142.3M
RESEARCH ONCOLOGY TRAINING GRANTT32CA059366 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI JACKSON, MARK W. · 1993 to 2025
$5.5M
HEMATOLOGY TRAINING UNITT32HL007147 · NHLBI · CASE WESTERN RESERVE UNIVERSITY · PI MCCRAE, KEITH R. · 1985 to 2010
$3.2M
GENE TRANSFER INTO HEMATOPOIETIC PROGENITORSR01CA073062 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI GERSON, STANTON L · 1997 to 2006
$1.8M
NCI NIH HHS P30 CA043703NCI NIH HHS P30CA43703NCI NIH HHS R01 CA073062NCI NIH HHS R01CA073062NCI NIH HHS T32 CA059366NCI NIH HHS T32CA059366NHLBI NIH HHS T32 HL007147NHLBI NIH HHS T32HL07147
6 · The paper itself

Abstract

The DNA repair gene O(6)-methylguanine-DNA methyltransferase (MGMT) allows efficient in vivo enrichment of transduced hematopoietic stem cells (HSC). Thus, linking this selection strategy to therapeutic gene expression offers the potential to reconstitute diseased hematopoietic tissue with gene-corrected cells. However, different dual-gene expression vector strategies are limited by poor expression of one or both transgenes. To evaluate different co-expression strategies in the context of MGMT-mediated HSC enrichment, we compared selection and expression efficacies in cells cotransduced with separate single-gene MGMT and GFP lentivectors to those obtained with dual-gene vectors employing either encephalomyocarditis virus (EMCV) internal ribosome entry site (IRES) or foot and mouth disease virus (FMDV) 2A elements for co-expression strategies. Each strategy was evaluated in vitro and in vivo using equivalent multiplicities of infection (MOI) to transduce 5-fluorouracil (5-FU) or Lin(-)Sca-1(+)c-kit(+) (LSK)-enriched murine bone marrow cells (BMCs). The highest dual-gene expression (MGMT(+)GFP(+)) percentages were obtained with the FMDV-2A dual-gene vector, but half of the resulting gene products existed as fusion proteins. Following selection, dual-gene expression percentages in single-gene vector cotransduced and dual-gene vector transduced populations were similar. Equivalent MGMT expression levels were obtained with each strategy, but GFP expression levels derived from the IRES dual-gene vector were significantly lower. In mice, vector-insertion averages were similar among cells enriched after dual-gene vectors and those cotransduced with single-gene vectors. These data demonstrate the limitations and advantages of each strategy in the context of MGMT-mediated selection, and may provide insights into vector design with respect to a particular therapeutic gene or hematologic defect.

Indexed as

Gene ExpressionAnimalsFluorouracilGene DosageGene OrderGenes, ReporterGenetic VectorsGene Transfer TechniquesHematopoietic Stem CellsHematopoietic Stem Cell TransplantationHumansK562 CellsLentivirusMiceO(6)-Methylguanine-DNA MethyltransferaseTransduction, GeneticFluorouracilO(6)-Methylguanine-DNA MethyltransferaseF2AGene therapyIRESLentivirusMGMTO(6)-methylguanine-DNA methyltransferaseP140K

Identifiers

PMID25479595
PMCPMC9667281
OpenAlexW2043498273

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.